Introduction {#s1}
============

Sound hospital infection control measures are critical for preventing and managing nosocomial tuberculosis (TB) outbreaks.[@R1],[@R2] This is especially true in wards caring for people living with human immunodeficiency virus (HIV) infection due to the heightened risk of TB among immunosuppressed patients.[@R3] Compounding this problem is the growing threat of multidrug-resistant tuberculosis (MDRTB), defined as strains of TB resistant to rifampin and isoniazid, because patients living with HIV infection and MDRTB infection have extremely high mortality and require complicated and expensive treatment.[@R4],[@R5]

Despite having a successful community-based national TB program since the 1990s,[@R6] hospital TB infection control in Peru has proven challenging.[@R7] Peruvian national surveillance data from 2012 estimated that 3.9% of new TB cases were caused by MDRTB; only 18% of TB patients knew their HIV status, and only 17% of patients living with HIV infection were tested for TB.[@R8] In Lima, Peru\'s capital, a study by Campos and others found that 35 of 81 (43%) HIV/TB coinfected patients sampled from 10 local hospitals between 1999 and 2000 were infected with MDRTB.[@R9]

Pyrazinamide (PZA) resistance is another important factor in TB control. PZA facilitates eradication of persistent bacteria and thus its incorporation into drug regimens is key to shortening treatment duration.[@R10]--[@R12] PZA resistance has been shown to be associated with mutations in the pyrazinamidase (PZAse) coding gene, *pncA*.[@R13],[@R14]

In the HIV ward of Lima\'s Hospital Dos de Mayo (HDM), we studied the utility of *pncA* mutation typing, in tandem with phenotypic resistance testing and spoligotyping, to detect nosocomial outbreaks and inform the hospital\'s new infection control practices.

Methods {#s2}
=======

Study design. {#s2a}
-------------

### Patient recruitment. {#s2a1}

An anonymized TB strain bank was compiled from clinical research studies that enrolled adults diagnosed with pulmonary TB in Lima, Peru, between 1999 and 2005. A total of 794 study patient primary isolates (one per patient) with confirmed culture-positive TB infection were opportunistically spoligotyped from the following four cohorts: 1) 241 of 282 study inpatients from the HDM HIV unit, 2) 329 of 385 study outpatients from Hospital Maria Auxiliadora, 3) all 155 unselected National TB Control Program study patients from 10 government clinics in north Lima, and 4) all 69 National TB Control Program study patients selected for high risk of TB or MDRTB from five government clinics in east Lima. Study recruitment has been previously reported,[@R5],[@R15]--[@R17] and all study protocols and consent forms were approved by the institutional review boards of Universidad Peruana Cayetano Heredia, Asociación Benéfica Proyectos en Informatica, Salud, Medicina, y Agricultura, Regional Ministry of Health of Lima, HDM, and/or the Johns Hopkins Bloomberg School of Public Health, and all participants gave informed, written consent.

### Infection control. {#s2a2}

Before 2001, all HIV-positive inpatients at HDM were admitted to a ward constituting one large room measuring 35 × 8 × 4.5 m height. Infection control measures consisted primarily of large windows that facilitated natural ventilation, and health-care workers in direct contact with patients were required to use protective N95 respirators. With the help of donor funds, a new respiratory isolation ward for all HIV-infected patients with suspected or confirmed TB opened in 2001, slightly over 2 years into the study, as part of an effort to improve the hospital\'s TB control measures. This ward separated these patients from their immunosuppressed HIV-positive TB-negative counterparts for the first time. The new ward was equipped with a mechanically ventilated negative pressure air filtration system. Additional control measures implemented concurrently included relocation of the waiting area for outpatients to an outdoor space in the adjacent gardens, and mandatory sputum smear microscopy for all patients with respiratory symptoms at the time of hospitalization. Further details outlining the design, implementation, impact, and cost-effectiveness of this intervention are presented in the accompanying article in this issue. Second-line drugs were not universally available at HDM until 2004. A separate study evaluating the effects of ultraviolet germicidal light on TB transmission was conducted from 2002 to 2004 in the isolation ward. For the duration of this study, these lights were switched off and on for alternate 24-hour periods.[@R18]

It is important to note that although we discuss our data before and after this infection control intervention in both the HIV-positive HDM inpatients and the HIV-negative outpatients from other sites, the intervention only took place in the HIV-positive HDM inpatients, whereas there was no infection control intervention in the HIV-negative outpatients from other sites whose data are used solely for simultaneous comparison of prevalence.

### Defining drug resistance. {#s2a3}

Spoligotyping data were available for all isolates. Multidrug resistance was determined by microplate colorimetric[@R19] and microscopic-observation drug-susceptibility (MODS)[@R15],[@R16],[@R20] assays. Multidrug resistance data were unavailable for 12 isolates due to issues with the growth of the isolate in these assays.

PZA resistance was determined by the standard Wayne test,[@R21] the results of which were available for all but 193 isolates. Although the Wayne test is an indirect biochemical test, it was shown to be a good predictor of PZA resistance demonstrated via the BACTEC 460TB and MGIT960 systems (Becton Dickinson Diagnostics, Sparks, MD) in the 127 isolates for which these test results were available (Pearson\'s correlation coefficient, *R* = 0.74). In particular, the Wayne test accurately predicted the PZA resistance of our two most prevalent mutations (13/14 in agreement for D49N and 4/4 in agreement for T135P) and our wild-type isolates (52/55 in agreement).

A total of 262 isolates, including all confirmed PZA-resistant strains and almost all MDR (131/135) strains, along with an equal number of randomly selected drug-susceptible strains, were tested for mutations in the *pncA* gene by DNA sequencing.[@R22]

Data analysis. {#s2b}
--------------

Pearson\'s χ^2^ test for independence was used to compare categorical variables. Simple logistic regressions for both MDR and PZA resistance were performed for relevant independent variables such as genotype, HIV status, age, and sex. Best-fit models were created by backwards selection to include only those variables with statistical significance in both the simple and multiple models. Nested models were compared using the likelihood ratio test. Spoligotype was defined as an indicator variable to compare each of the five most prevalent genotypes---spoligotype international type (SIT) numbers 50, 53, 33, 42, and 1---with all other genotypes grouped together. The best-fit models were repeated with the addition of the interaction terms of HIV status on genotype to examine for potential effect modification. Odds ratios (ORs) were calculated using logistic regression and were adjusted for age and gender. All *P* values were two sided and *P* \< 0.05 was considered statistically significant. Analysis was performed using STATA/IC 12.1 software (STATA Corp., College Station, TX).

Results {#s3}
=======

Patients. {#s3a}
---------

A total of 794 study patients diagnosed with a new TB episode with a positive culture had their *Mycobacterium tuberculosis* strain spoligotyped.[@R17] All 241 HDM patients were HIV seropositive (30% of total), and all other patients were HIV negative or of unknown HIV status ([Table 1](#tab1){ref-type="table"}). The outpatients of unknown HIV status were assumed to be HIV negative for the purpose of this analysis because the prevalence of HIV infection in Peru was less than 0.5% of the general population, and 1.7% of TB patients.[@R5]

Genotypes using SIT numbers. {#s3b}
----------------------------

Of these 794 isolates, 149 different spoligotypes were identified. The five most common TB genotypes among all patients were SIT 50 of the Harlem3 clade (16% of all isolates), SIT 53 of the T1 clade (12%), SIT 33 of the Latino American-Mediterranean (LAM)-3 clade (8.3%), SIT 42 of the LAM9 clade (7.4%), and SIT 1 of the Beijing clade (5.5%). Together, these five genotypes comprised 397 (50%) of the TB isolates ([Table 1](#tab1){ref-type="table"}).

Drug resistance. {#s3c}
----------------

PZA resistance, defined according to the Wayne test, was detected in 16% of isolates overall. Of the MDR isolates tested, 59% were also PZA resistant, compared with just 3.6% of non-MDR isolates tested ([Table 1](#tab1){ref-type="table"}).

MDR and PZA resistance were strongly correlated (Pearson\'s correlation coefficient, *R* = 0.63). This correlation was seen even more clearly among HIV-positive inpatients (*R* = 0.79), compared with HIV-negative outpatients (*R* = 0.33).

Simple logistic regressions were performed to examine the associations of common genotypes, HIV status, age, and sex with drug resistance. Multiple logistic regression models were then created using the best-fit methods described in the data analysis section above. These revealed SIT 42 and SIT 53 to be the only genotypes to have statistically significant associations with both MDR and PZA resistance after adjusting for HIV status. In these models, SIT 42 had 12 times higher odds of being MDR and 12 times higher odds of PZA resistance than the less common genotypes, and SIT 53 had 3.8 times higher odds of being MDR and 5.0 times higher odds of PZA resistance. Patients living with HIV infection had 3.6 times higher odds of being MDR and 4.4 times higher odds of PZA resistance than patients without HIV infection, independent of the aforementioned genotypes (all *P* \< 0.001) ([Table 2](#tab2){ref-type="table"}).

Interaction terms between HIV and these genotypes were also explored but did not improve model fit. The model examining the interaction of SIT 42 and HIV coinfection on MDR was the only new model that retained some statistical significance ([Table 2](#tab2){ref-type="table"}).

*pncA* mutations. {#s3d}
-----------------

Of the 262 TB isolates examined for *pncA* mutations, the two most common were G145A (a D49N PZAse mutation) and A403C (a T135P PZAse mutation), found in 12% and 5.3% of examined isolates, respectively. All 32 G145A isolates were of the SIT 42 genotype, and all were MDR and PZA resistant. Of these isolates, 31 were from the HDM HIV ward. Likewise, all 15 of the A403C isolates were of the SIT 53 genotype, MDR, and PZA resistant; 11 of these were from the HDM HIV ward ([Table 3](#tab3){ref-type="table"}).

The only other common *pncA* mutation significantly associated with MDR and PZA resistance was C309G (a Y103Stop protein mutation), found in 3.4% of examined isolates. Eight of nine C309G isolates were MDR and PZA resistant, six of which were also SIT 53. All nine were from the HDM HIV ward ([Table 3](#tab3){ref-type="table"}).

ORs of genotype and drug-resistant infection after the implementation of the infection control intervention. {#s3e}
------------------------------------------------------------------------------------------------------------

As described above, an isolation ward for HIV/TB coinfected patients was opened in the HIV unit of HDM 2 years into the study as an infection control intervention. Among HDM patients, the odds of disease caused by MDRTB after the intervention was reduced by almost two-thirds compared with the odds before the intervention (OR = 0.35, *P* \< 0.001), and the odds of PZA-resistant TB disease after the intervention was reduced by over 90% compared with the odds before the intervention (OR = 0.076, *P* \< 0.001). The odds of TB disease after the intervention caused by either SIT 42 or SIT 53, the genotypes with the strongest associations with drug resistance, was reduced by over half (OR = 0.420, *P* = 0.003). The odds of TB disease caused by SIT 50, the most common community strain, increased slightly after the intervention (OR = 1.729, *P* = 0.271), whereas the odds of disease caused by other common drug-susceptible community strains such as SIT 33 and SIT 1 were almost entirely unchanged ([Table 4](#tab4){ref-type="table"}).

By comparison, among community patients, the odds of PZA-resistant TB disease after the intervention increased only slightly (OR = 1.3, *P* = 0.7), and the prevalence of each of the five most common genotypes (SIT 42, 53, 50, 33, and 1) remained relatively constant, changing by no more than 2.5% ([Table 4](#tab4){ref-type="table"}). Of interest, however, is that the odds of MDRTB infection among community patients actually increased after the intervention by more than 3-fold (OR = 3.7, *P* = 0.04). This indicates that as MDRTB infection was becoming less common in the HIV ward, it was becoming increasingly common in the community.

Prevalence of SIT 42 over time. {#s3f}
-------------------------------

Before the intervention, the highly drug-resistant genotypes SIT 42 and SIT 53 were present in the HIV ward of HDM. In the first year of the study, prevalence of both SIT 42 and SIT 53 was much higher in HDM than in the community (15% versus 3.6% and 27% versus 12% of cases, *P* = 0.003 and *P* = 0.007, respectively). In the second year, the prevalence of SIT 42 in HDM increased dramatically to 39% of cases, whereas prevalence in the community stayed nearly the same at 3.8% of cases (*P* \< 0.001).

In the first year of use of the HDM new isolation ward, prevalence of SIT 42 among inpatients decreased to 29% of cases, and again the next year to 13% of cases. Prevalence continued to decrease in the years that followed, and within 3 years of the intervention, SIT 42 was no longer detected in the HDM cohort ([Figure 1](#fig1){ref-type="fig"} Figure 1.Change in prevalence over time of highly drug-resistant nosocomial outbreak strains SIT 42 and SIT 53 vs. non-drug-resistant predominant community strain SIT 50 in Hospital Dos de Mayo inpatients living with human immunodeficiency virus infection. Intervention marked with vertical line. SIT 42 and SIT 53 highly drug-resistant nosocomial outbreak strains. SIT 50 non-drug-resistant predominant community strain. SIT = spoligotype international type.). During this time, prevalence of SIT 42 in the community remained fairly constant ([Figure 2](#fig2){ref-type="fig"} Figure 2.Change in prevalence over time of five common strains in community outpatients without human immunodeficiency virus infection. SIT = spoligotype international type.).

Discussion {#s4}
==========

The data characterize an outbreak of TB genotype SIT 42 (LAM9 clade), and possibly also SIT 53 (T1 clade), among inpatients in a hospital HIV ward during a 6-year period. The high prevalence of SITs 42 and 53 was not observed with the other TB genotypes circulating in the HDM population, nor in the community outpatients without HIV infection during the same period. Transmission of SITs 42 and 53 decreased substantially after implementation of the new isolation ward. This suggests that these two strains were related to the nosocomial spread of MDR and PZA-resistant TB within the HDM population, and demonstrates the effectiveness of control measures such as negative pressure ventilation, use of rapid diagnostics, and source isolation in this resource-constrained setting.

The two most common *pncA* gene mutations in this study, G145A (D49N PZAse mutation) and A403C (T135P PZAse mutation), were found exclusively in the SIT 42 and SIT 53 isolates, respectively. All isolates with one of these two mutations were shown to be MDR and PZA resistant; unsurprisingly, SIT 42 and SIT 53 were also shown to be strongly associated with MDR and PZA resistance among HIV-positive HDM inpatients. No significant association with drug resistance was found for these two genotypes among HIV-negative community patients nor in any other common TB genotypes regardless of HIV status. MDR and PZA resistance were highly correlated especially among patients living with HIV infection. However, the association between drug resistance and these two SIT genotypes remained significant even after controlling for the confounding of HIV status.

A study using a guinea pig model to examine the airborne infectiousness of TB in the HIV ward at HDM showed that a very small number of MDRTB patients were responsible for the vast majority of TB transmission.[@R23] This could explain the rapid and sustained transmission of the drug-resistant SIT 42 and SIT 53 strains within the HIV-positive HDM population compared with other genotypes.

In several large Peruvian hospitals, inpatients with infectious diseases have historically shared a large open ward without engineering for air extraction.[@R9] This greatly increases the likelihood of person-to-person TB transmission.[@R7],[@R24] HDM, the source of all patients living with HIV infection in this study, operated under these conditions until use of a new respiratory isolation ward for TB patients began in 2001, 2 years into this study. This intervention was associated with a significant decrease in rates of MDRTB, from 56% to 20% among HIV/TB coinfected patients (see the accompanying article in this issue). The effectiveness of the intervention is apparent from the rapid, sustained reduction in transmission of SIT 42, culminating in a complete cessation of transmission of this genotype within 3 years of the new ward opening. Transmission of SIT 53 did not decrease immediately nor stop completely before the end of the study. However, odds of both MDR and PZA-resistant infection decreased significantly after the intervention.

Another notable factor is that SIT 53 had a higher prevalence than SIT 42 in the HIV-negative community population throughout the study (10--3.4% of cases, respectively). In fact, community prevalence of SIT 53 was second only to SIT 50 (Harlem3 clade), a mostly drug-sensitive strain. One possible explanation for the slower decrease in prevalence of SIT 53 compared with SIT 42 after the intervention is that new TB infections in HDM before the intervention were mostly due to intrahospital spread of drug-resistant strains, whereas after the intervention, new TB infections were no longer dominated by intrahospital transmission and began to more closely resemble the distribution seen in the community. This would also explain the increase in prevalence of SIT 50 in the HIV-positive HDM population after the intervention: the most common community strain replaced the dwindling nosocomial strains.

An unexpected trait of our spoligotyping data is the relative unimportance of the SIT 1 genotype of the Beijing family. This strain accounted for less than 6% of patients, and showed no association with drug resistance. This is surprising considering the historical association between Beijing family strains and drug resistance.[@R25] A differential evolution of drug resistance might be occurring, without being linked to the mentioned genotyping test markers.

To diagnose TB, sputum smear microscopy was mandatory in all patients with respiratory symptoms who could produce sputum. Smear microscopy has advantages of being inexpensive and highly specific. However, it is also poorly sensitive leading to many false-negative results, and it cannot diagnose drug resistance. The MODS assay was also used in this study to determine multidrug resistance. This assay has been shown to be an inexpensive, sensitive, and specific diagnostic option,[@R15],[@R16],[@R20] and the incorporation of TB drugs into the culture medium allows for the determination of antimicrobial sensitivity to rifampin and isoniazid. Recently, it has also been validated for the detection of extensively drug-resistant TB.[@R26] The GeneXpert MTB/RIF (Cepheid, Sunnyvale, CA) machine is another potentially useful diagnostic option that detects drug resistance very rapidly.[@R27] Hospital TB control measures should incorporate use of at least one of the available rapid tools for TB diagnosis and detection of drug resistance, and use this information to separate patients and to ensure that all patients receive appropriate, effective treatment. The diagnostic tool that is most appropriate for a particular hospital will depend on factors such as budget, available laboratory equipment and personnel, and the characteristics of the patient population.

Limitations of this study include time gaps in data from the HIV-negative community population, which was most evident between years 3 and 4, and missing data (Wayne test administered to only 601 of 794 isolates, *pncA* mutation data only available for 262).

Conclusions {#s5}
===========

Lack of effective infection control measures in an HIV ward favored the ongoing transmission of two highly drug-resistant TB genotypes, SIT 42 and SIT 53. The pervading resistance to PZA found to be associated with these two genotypes can be explained by their strong association with G145A and A403C *pncA* mutations, respectively. The installation of a new respiratory isolation ward at HDM for HIV-positive patients with suspected or confirmed TB greatly decreased nosocomial transmission of these drug-resistant TB strains.

We have shown for the first time the utility of mutation typing when combined with resistance testing and spoligotyping in detecting and characterizing TB outbreaks. Our findings also reinforce the importance of implementing hospital infection control measures, including rapid susceptibility testing and patient isolation, to prevent the spread of drug-resistant TB, especially among patients living with HIV.
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###### 

Demographic characteristics, drug resistance characteristics, and *Mycobacterium tuberculosis* genotypes among hospitalized HIV-positive patients and HIV-negative outpatients

                                                                            HIV positive *n* (%)   HIV negative *n* (%)[†](#tfn3){ref-type="table-fn"}   Total *n* (%)                         *P* value[§](#tfn5){ref-type="table-fn"}
  ------------------------------------------------------------------------- ---------------------- ----------------------------------------------------- ------------------------------------- ------------------------------------------
  Total patients                                                            241 (30)               553 (70)                                              794 (100)                             
  Demographic characteristics                                                                                                                                                                  
   Age in years, mean (standard deviation)                                  32 (7.8)               31 (13)                                               563[\*](#tfn2){ref-type="table-fn"}   0.4
   Age range                                                                18--63                 15--78                                                                                      
   Gender                                                                                                                                                792[\*](#tfn2){ref-type="table-fn"}   
    Female                                                                  49 (21)                241 (44)                                              290 (37)                              
    Male                                                                    190 (80)               312 (56)                                              502 (63)                              \< 0.001
  Drug resistance characteristics[¶](#tfn6){ref-type="table-fn"}                                                                                                                               
   PZA resistant                                                            64 (34)                30 (7.3)                                              94 (16)                               \< 0.001
   MDR                                                                      82 (35)                53 (9.7)                                              135 (17)                              \< 0.001
    MDR with PZA resistance                                                 62 (78)                15 (30)                                               77 (59)                               
  *pncA* mutation present[∥](#tfn7){ref-type="table-fn"}                    69 (50)                35 (29)                                               104 (40)                              \< 0.001
  No. of unique spoligotypes                                                59 (24)                127 (23)                                              149 (19)                              
  SIT (clade) in order of total prevalence[‡](#tfn4){ref-type="table-fn"}                                                                                                                      
   Id. 177 SIT 50 (Harlem3)                                                 25 (10)                105 (19)                                              130 (16)                              0.003
   Id. 188 SIT 53 (T1)                                                      41 (17)                57 (10)                                               98 (12)                               0.008
   Id. 75 SIT 33 (LAM3)                                                     12 (5)                 54 (10)                                               66 (8)                                0.03
   Id. 144 SIT 42 (LAM9)                                                    40 (17)                19 (3)                                                59 (7)                                \< 0.001
   Id. 3 SIT 1 (Beijing)                                                    9 (4)                  35 (6)                                                44 (6)                                0.1
   Id. 161 SIT 47 (Harlem1)                                                 5 (2)                  26 (5)                                                31 (4)                                0.08
   Id. 130 SIT 1355 (T2)                                                    11 (5)                 13 (2)                                                24 (3)                                0.09
   Id. 118 SIT 222 (T1)                                                     6 (2)                  18 (3)                                                24 (3)                                0.6
   Id. 47 SIT 91 (X3)                                                       7 (3)                  15 (3)                                                22 (3)                                0.9
  All other genotypes                                                       85 (35)                211 (38)                                              296 (37)                              

HIV = human immunodeficiency virus; LAM = Latino American-Mediterranean TB clade; MDR = multidrug resistant; PZA = pyrazinamide; SIT = spoligotype international type; TB = tuberculosis.

Missing values (age, *N* = 231; and gender, *N* = 2).

HIV negative or unknown.

Phylogenetic clade assigned according to spolDB4 Pasteur database, SIT number given when the clade is represented by a unique prototype as defined in SpolDB4 Pasteur database.

*P* value for the Pearson χ^2^ proportion test at significance level of (α) 5%.

MDR test performed in 782 isolates, Wayne test for PZA resistance performed in 601 isolates, 187 of which were HIV seropositive and 130 of which were MDR.

*pncA* mutation data available for 262 isolates, 139 of which were HIV seropositive.

###### 

Association between common *Mycobacterium tuberculosis* genotypes and drug-resistant phenotype adjusted for relevant variables

  Independent variable     MDR                                                                                                                                                            
  ------------------------ ------------------------------------------------------------ ------------------------------------- ----------- ------ ---------- ----------- ----- ----------- ----------
  SIT 1 (Beijing)          0.69                                                         0.24--2.0                             0.5                                                         
  SIT 33 (LAM3)            0.11                                                         0.01--0.80                            0.03                                                        
  SIT 42 (LAM9)            14                                                           7.30--25                              \< 0.001    12     6.3--22    \< 0.001    2.6   0.83--8.2   0.1
  SIT 50 (Harlem3)         0.59                                                         0.29--1.2                             0.144                                                       
  SIT 53 (T1)              3.4                                                          2.0--5.7                              \< 0.001    3.8    2.2--6.3   \< 0.001                      
  HIV status               5.0                                                          3.4--7.4                              \< 0.001    3.6    2.3--5.5   \< 0.001    3.1   2.0--4.8    \< 0.001
  Age                      0.99                                                         0.97--1.0                             0.2                                                         
  Sex                      1.5                                                          1.0--2.3                              0.045                                                       
  HIV/SIT 42 interaction                                                                                                                                                8.5   1.9--38     0.006
  Pseudo *R*^2^                                                                                                                           0.20   0.18                                     
                           PZA resistance                                                                                                                                                 
                           Simple logistic regression[\*](#tfn9){ref-type="table-fn"}   MLR[†](#tfn10){ref-type="table-fn"}                                                               
                           OR                                                           CI                                    *P* value   OR     CI         *P* value                     
  SIT 1 (Beijing)          0.36                                                         0.05--2.8                             0.331                                                       
  SIT 33 (LAM3)            NA                                                                                                                                                             
  SIT 42 (LAM9)            15                                                           7.9--30                               \< 0.001    12     5.9--23    \< 0.001                      
  SIT 50 (Harlem3)         0.89                                                         0.38--2.1                             0.8                                                         
  SIT 53 (T1)              4.9                                                          2.7--9.1                              \< 0.001    5.0    2.7--9.3   \< 0.001                      
  HIV status               6.7                                                          4.1--11                               \< 0.001    4.4    2.6--7.4   \< 0.001                      
  Age                      0.99                                                         0.97--1.0                             0.3                                                         
  Sex                      0.94                                                         0.60--1.5                             0.8                                                         

CI = confidence interval; HIV = human immunodeficiency virus; LAM = Latino American-Mediterranean TB clade; MDR = multidrug resistant; MLR = multiple logistic regression; OR = odds ratio; PZA = pyrazinamide; NA = not applicable due to model omission, predicts failure perfectly; SIT = spoligotype international type.

Simple logistic regression using MDR or PZA resistance as dependent variable. An indicator variable for SIT genotype compares each of these five most common SITs against all SITs other than these five.

Multiple logistic regression using MDR or PZA resistance as dependent variable and SIT 42 and SIT 53 as independent variables of interest, adjusted for HIV status. Model chosen by backwards selection until all variables were statistically significant at level of (α) 5%.

Multiple logistic regression using MDR as dependent variable and SIT 42, HIV, and an interaction term for HIV multiplied by SIT 42.

###### 

HIV status, drug resistance characteristics, and genotype associations of common *pncA* mutations

  Protein mutation                              DNA mutation   HIV+                                             \%[§](#tfn16){ref-type="table-fn"}   [†](#tfn14){ref-type="table-fn"}HIV−        \%[§](#tfn16){ref-type="table-fn"}   *P* value[‡](#tfn15){ref-type="table-fn"}   Total    \%[§](#tfn16){ref-type="table-fn"}   MDR   \%[¶](#tfn17){ref-type="table-fn"}   *P* value[\*](#tfn13){ref-type="table-fn"}
  --------------------------------------------- -------------- ------------------------------------------------ ------------------------------------ ------------------------------------------- ------------------------------------ ------------------------------------------- -------- ------------------------------------ ----- ------------------------------------ --------------------------------------------
  D49N                                          G145A          31                                               22                                   1                                           0.8                                  \< 0.001                                    32       12                                   32    100                                  \< 0.001
  T135P                                         A403C          11                                               7.9                                  4                                           3.3                                  0.1                                         15       5.3                                  15    100                                  \< 0.001
  Y103Stop                                      C309G          9                                                6.5                                  0                                           0.0                                  0.004                                       9        3.4                                  8     89                                   0.02
  K48T                                          A143C          3                                                2.2                                  5                                           4.1                                  0.4                                         8        3.1                                  7     88                                   0.03
  H51R                                          A152G          3                                                2.2                                  4                                           3.3                                  0.6                                         7        2.7                                  3     43                                   0.7
  All others (25 types, ≤ 3 isolates of each)   12             8.6                                              21                                   17                                          0.04                                 33                                          13       25                                   76    0.002                                
  wild type                                     70             50                                               88                                   72                                          \< 0.001                             158                                         60       41                                   26    \< 0.001                             
  Total (with mutation data)                    139            100                                              123                                  100                                                                              262                                         100      131                                  50                                         
  Total mutations                               69             50                                               35                                   29                                          \< 0.001                             104                                         40       90                                   87    \< 0.001                             
  Protein mutation                              DNA mutation   PZA resistant[\*](#tfn13){ref-type="table-fn"}   \%                                   *P* value[‡](#tfn15){ref-type="table-fn"}   SIT 42                               \%[¶](#tfn17){ref-type="table-fn"}          SIT 53   \%[¶](#tfn17){ref-type="table-fn"}                                              
  D49N                                          G145A          32/32                                            100                                  \< 0.001                                    32                                   100                                         0        0                                                                               
  T135P                                         A403C          15/15                                            100                                  \< 0.001                                    0                                    0                                           15       100                                                                             
  Y103stop                                      C309G          8/9                                              89                                   \< 0.001                                    0                                    0                                           6        67                                                                              
  K48T                                          A143C          0/7                                              0                                    0.054                                       0                                    0                                           0        0                                                                               
  H51R                                          A152G          5/7                                              71                                   0.035                                       1                                    14                                          0        0                                                                               
  All others (25 types, ≤ 3 isolates of each)   17/31          55                                               0.009                                                                            4                                    12                                          4        12                                                                              
  Wild type                                     11/154         7.1                                              \< 0.001                                                                         6                                    3.8                                         22       14                                                                              
  Total (with mutation data)                    87/255         34                                                                                                                                43                                   16                                          47       18                                                                              
  Total mutations                               76/101         75                                               \< 0.001                                                                         37                                   36                                          25       24                                                                              

HIV = human immunodeficiency virus; LAM = Latino American-Mediterranean TB clade; MDR = multidrug resistant; PZA = pyrazinamide; SIT = spoligotype international type.

Missing values (Wayne test data for PZA resistance on 255 of 262 isolates with mutation data).

HIV negative or unknown status.

*P* value for the Pearson χ^2^ proportion test at significance level of (α) 5%.

Percentage of total (with mutation data) row.

Percentage of total column.

Percentage of total column with available PZA resistance data.

###### 

Characteristics of TB isolates and odds of infection before and after implementation of the new TB infection control intervention in Hospital Dos de Mayo

                     HDM patients living with HIV infection and receiving intervention   Before new ward   Community patients receiving no intervention[§](#tfn23){ref-type="table-fn"}                                                                        
  ------------------ ------------------------------------------------------------------- ----------------- ------------------------------------------------------------------------------ ----- ------- ---------- -------- ----- -------- ----- ------ ------ --
  Drug resistance                                                                                          Intervention[‡](#tfn22){ref-type="table-fn"}                                                                                                        
  MDR                40/78                                                               51                42/157                                                                         27    0.35    \< 0.001   13/270   4.8   40/277   14    3.7    0.04   
  PZA                35/47                                                               74                29/140                                                                         21    0.076   \< 0.001   12/173   6.9   18/241   7.5   1.3    0.7    
  Genotype                                                                                                                                                                                                                                                     
  SIT 42 (LAM9)      19                                                                  24                21                                                                             13    0.51    0.06       10       3.7   9        3.2   0.62   0.5    
  SIT 50 (Harlem3)   6                                                                   7.5               19                                                                             12    1.7     0.3        48       18    57       20    0.81   0.5    
  SIT 53 (T1)        18                                                                  23                23                                                                             14    0.51    0.07       29       11    28       9.9   1.07   0.9    
  SIT 33 (LAM3)      4                                                                   5.0               8                                                                              5.0   1.3     0.7        27       10    27       9.5   0.59   0.2    
  SIT 1 (Beijing)    3                                                                   3.8               6                                                                              3.7   0.92    0.9        20       7.4   15       5.3   0.79   0.7    
  All others         30                                                                  38                84                                                                             52    1.8     0.04       136      50    147      52    1.6    0.1    
  Total              80                                                                  100               161                                                                            100                      270      100   283      100                 
  SIT 42 or SIT 53   37                                                                  46                44                                                                             27    0.42    0.003      39       14    37       13    0.90   0.8    

CI = confidence interval; HDM = Hospital Dos de Mayo; HIV = human immunodeficiency virus; MDR = multidrug resistant; OR = odds ratio; PZA = pyrazinamide; TB = tuberculosis; SIT = spoligotype international type.

OR comparing odds after to before intervention, adjusted by age and gender, determined by logistic regression.

*P* value for the OR coefficient for the intervention.

Intervention: use of new TB ward in HDM separating TB and HIV patients began 2 years into the study.

HIV negative or unknown status.
